» Articles » PMID: 3026575

Beta-carbolines Characterized As Benzodiazepine Receptor Agonists and Inverse Agonists Produce Bi-directional Changes in Palatable Food Consumption

Overview
Journal Brain Res Bull
Specialty Neurology
Date 1986 Nov 1
PMID 3026575
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Drugs which bind to specific benzodiazepine recognition sites fall into three categories: agonists, antagonists, and inverse agonists. A set of biochemical parameters is available which distinguishes between the three. In addition, actions of the drugs result in physiological and behavioural effects which are distinguishable. beta-Carboline derivatives provide a group of compounds which show high affinity for the benzodiazepine sites, and which contains examples belonging to each of the three categories. Evidence is reviewed which shows that beta-carboline benzodiazepine receptor agonists (ZK 93423, ZK 91296) produce increases in the consumption of a palatable diet by non-deprived rats, that beta-carboline inverse agonists (FG 7142, DMCM) produce an anorectic effect, and that the beta-carboline ZK 93426 acts as a benzodiazepine receptor antagonist. The results support the proposal of bi-directional control of feeding responses through the action of drugs at a common benzodiazepine receptor. Furthermore, benzodiazepine receptor inverse agonists provide a novel class of anorectic agents. Evidence is also reviewed which is suggestive of the modulation of food-related reward by drug actions at benzodiazepine receptors.

Citing Articles

Obesity and Brain Positron Emission Tomography.

Pak K, Kim S, Kim I Nucl Med Mol Imaging. 2018; 52(1):16-23.

PMID: 29391908 PMC: 5777956. DOI: 10.1007/s13139-017-0483-8.


Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice.

Belzung C, Misslin R, Vogel E Psychopharmacology (Berl). 1989; 97(3):388-91.

PMID: 2566186 DOI: 10.1007/BF00439456.


Discriminative stimulus properties of the benzodiazepine receptor antagonist flumazenil.

Rowan G, Lucki I Psychopharmacology (Berl). 1992; 107(1):103-12.

PMID: 1317039 DOI: 10.1007/BF02244973.